PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DARULOTAMIDE
Disclosed herein are pharmaceutical compositions comprising Abiraterone acetate and Darolutamide, which are useful in the treatment of a type of prostate cancer. The pharmaceutical composition possesses increased in- vitro permeability both in fasted and fed state which allows significant dose reduc...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GLAVINAS, Hristos UJHELYI, Andrea SZABÓNÉ ORDASI, Betti JORDÁN, Tamás SOLYMOSI, Tamás ERDOSI, Nikoletta |
| description | Disclosed herein are pharmaceutical compositions comprising Abiraterone acetate and Darolutamide, which are useful in the treatment of a type of prostate cancer. The pharmaceutical composition possesses increased in- vitro permeability both in fasted and fed state which allows significant dose reduction and the abandoning of the requirement of taking the drugs on an empty stomach. Further disclosed are methods of formulating and manufacturing the pharmaceutical composition, its uses and methods of treatment using the pharmaceutical composition.
L'invention concerne des compositions pharmaceutiques qui comportent de l'acétate d'abiratérone et du darolutamide et qui sont utilisables dans le traitement d'un type de cancer de la prostate. La composition pharmaceutique possède une perméabilité in vitro augmentée, aussi bien à jeun qu'après une prise d'aliments, ce qui permet une diminution significative de la dose et l'abandon de l'exigence d'une prise de médicaments à jeun. L'invention concerne en outre des procédés de préparation et de fabrication de la composition pharmaceutique, ses utilisations, ainsi que des méthodes de traitement utilisant la composition pharmaceutique. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2019032840A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2019032840A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2019032840A13</originalsourceid><addsrcrecordid>eNrjZPAK8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH09wOzgzyDPf3cFRydPIMcQ1yD_P1cFYCKQ4BsBUc_FwUXx6BQH_8QR19PF1ceBta0xJziVF4ozc2g7OYa4uyhm1qQH59aXJCYnJqXWhIf7m9kYGhpYGxkYWLgaGhMnCoAReMung</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DARULOTAMIDE</title><source>esp@cenet</source><creator>GLAVINAS, Hristos ; UJHELYI, Andrea ; SZABÓNÉ ORDASI, Betti ; JORDÁN, Tamás ; SOLYMOSI, Tamás ; ERDOSI, Nikoletta</creator><creatorcontrib>GLAVINAS, Hristos ; UJHELYI, Andrea ; SZABÓNÉ ORDASI, Betti ; JORDÁN, Tamás ; SOLYMOSI, Tamás ; ERDOSI, Nikoletta</creatorcontrib><description>Disclosed herein are pharmaceutical compositions comprising Abiraterone acetate and Darolutamide, which are useful in the treatment of a type of prostate cancer. The pharmaceutical composition possesses increased in- vitro permeability both in fasted and fed state which allows significant dose reduction and the abandoning of the requirement of taking the drugs on an empty stomach. Further disclosed are methods of formulating and manufacturing the pharmaceutical composition, its uses and methods of treatment using the pharmaceutical composition.
L'invention concerne des compositions pharmaceutiques qui comportent de l'acétate d'abiratérone et du darolutamide et qui sont utilisables dans le traitement d'un type de cancer de la prostate. La composition pharmaceutique possède une perméabilité in vitro augmentée, aussi bien à jeun qu'après une prise d'aliments, ce qui permet une diminution significative de la dose et l'abandon de l'exigence d'une prise de médicaments à jeun. L'invention concerne en outre des procédés de préparation et de fabrication de la composition pharmaceutique, ses utilisations, ainsi que des méthodes de traitement utilisant la composition pharmaceutique.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TESTING</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190214&DB=EPODOC&CC=WO&NR=2019032840A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190214&DB=EPODOC&CC=WO&NR=2019032840A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GLAVINAS, Hristos</creatorcontrib><creatorcontrib>UJHELYI, Andrea</creatorcontrib><creatorcontrib>SZABÓNÉ ORDASI, Betti</creatorcontrib><creatorcontrib>JORDÁN, Tamás</creatorcontrib><creatorcontrib>SOLYMOSI, Tamás</creatorcontrib><creatorcontrib>ERDOSI, Nikoletta</creatorcontrib><title>PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DARULOTAMIDE</title><description>Disclosed herein are pharmaceutical compositions comprising Abiraterone acetate and Darolutamide, which are useful in the treatment of a type of prostate cancer. The pharmaceutical composition possesses increased in- vitro permeability both in fasted and fed state which allows significant dose reduction and the abandoning of the requirement of taking the drugs on an empty stomach. Further disclosed are methods of formulating and manufacturing the pharmaceutical composition, its uses and methods of treatment using the pharmaceutical composition.
L'invention concerne des compositions pharmaceutiques qui comportent de l'acétate d'abiratérone et du darolutamide et qui sont utilisables dans le traitement d'un type de cancer de la prostate. La composition pharmaceutique possède une perméabilité in vitro augmentée, aussi bien à jeun qu'après une prise d'aliments, ce qui permet une diminution significative de la dose et l'abandon de l'exigence d'une prise de médicaments à jeun. L'invention concerne en outre des procédés de préparation et de fabrication de la composition pharmaceutique, ses utilisations, ainsi que des méthodes de traitement utilisant la composition pharmaceutique.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPAK8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH09wOzgzyDPf3cFRydPIMcQ1yD_P1cFYCKQ4BsBUc_FwUXx6BQH_8QR19PF1ceBta0xJziVF4ozc2g7OYa4uyhm1qQH59aXJCYnJqXWhIf7m9kYGhpYGxkYWLgaGhMnCoAReMung</recordid><startdate>20190214</startdate><enddate>20190214</enddate><creator>GLAVINAS, Hristos</creator><creator>UJHELYI, Andrea</creator><creator>SZABÓNÉ ORDASI, Betti</creator><creator>JORDÁN, Tamás</creator><creator>SOLYMOSI, Tamás</creator><creator>ERDOSI, Nikoletta</creator><scope>EVB</scope></search><sort><creationdate>20190214</creationdate><title>PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DARULOTAMIDE</title><author>GLAVINAS, Hristos ; UJHELYI, Andrea ; SZABÓNÉ ORDASI, Betti ; JORDÁN, Tamás ; SOLYMOSI, Tamás ; ERDOSI, Nikoletta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2019032840A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2019</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>GLAVINAS, Hristos</creatorcontrib><creatorcontrib>UJHELYI, Andrea</creatorcontrib><creatorcontrib>SZABÓNÉ ORDASI, Betti</creatorcontrib><creatorcontrib>JORDÁN, Tamás</creatorcontrib><creatorcontrib>SOLYMOSI, Tamás</creatorcontrib><creatorcontrib>ERDOSI, Nikoletta</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GLAVINAS, Hristos</au><au>UJHELYI, Andrea</au><au>SZABÓNÉ ORDASI, Betti</au><au>JORDÁN, Tamás</au><au>SOLYMOSI, Tamás</au><au>ERDOSI, Nikoletta</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DARULOTAMIDE</title><date>2019-02-14</date><risdate>2019</risdate><abstract>Disclosed herein are pharmaceutical compositions comprising Abiraterone acetate and Darolutamide, which are useful in the treatment of a type of prostate cancer. The pharmaceutical composition possesses increased in- vitro permeability both in fasted and fed state which allows significant dose reduction and the abandoning of the requirement of taking the drugs on an empty stomach. Further disclosed are methods of formulating and manufacturing the pharmaceutical composition, its uses and methods of treatment using the pharmaceutical composition.
L'invention concerne des compositions pharmaceutiques qui comportent de l'acétate d'abiratérone et du darolutamide et qui sont utilisables dans le traitement d'un type de cancer de la prostate. La composition pharmaceutique possède une perméabilité in vitro augmentée, aussi bien à jeun qu'après une prise d'aliments, ce qui permet une diminution significative de la dose et l'abandon de l'exigence d'une prise de médicaments à jeun. L'invention concerne en outre des procédés de préparation et de fabrication de la composition pharmaceutique, ses utilisations, ainsi que des méthodes de traitement utilisant la composition pharmaceutique.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2019032840A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING |
| title | PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DARULOTAMIDE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T00%3A51%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GLAVINAS,%20Hristos&rft.date=2019-02-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2019032840A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |